Fragment Discovery for the Design of Nitrogen Heterocycles as<i>Mycobacterium tuberculosis</i>Dihydrofolate Reductase Inhibitors
作者:Rupesh U. Shelke、Mariam S. Degani、Archana Raju、Mukti Kanta Ray、Mysore G. R. Rajan
DOI:10.1002/ardp.201600066
日期:2016.8
Fragment‐based drug design was used to identify Mycobacterium tuberculosis (Mtb) dihydrofolate reductase (DHFR) inhibitors. Screening of ligands against the Mtb DHFR enzyme resulted in the identification of multiple fragment hits with IC50 values in the range of 38–90 μM versus Mtb DHFR and minimum inhibitory concentration (MIC) values in the range of 31.5–125 μg/mL. These fragment scaffolds would
基于片段的药物设计用于鉴定结核分枝杆菌 (Mtb) 二氢叶酸还原酶 (DHFR) 抑制剂。针对 Mtb DHFR 酶的配体筛选导致鉴定出多个片段命中,IC50 值在 38-90 μM 范围内,而最小抑制浓度 (MIC) 值在 31.5-125 μg/mL 范围内。这些片段支架可用于抗结核药物设计。